(Q34030120)

30 July 2017

1 reference

title

Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

30 July 2017

1 reference

Cazzola M

1

1 reference

PubMed ID

10983735

30 July 2017

Donner CF

series ordinal

2

1 reference

30 July 2017

1 August 2000

1 reference

30 July 2017

1 reference

30 July 2017

60

1 reference

30 July 2017

2

1 reference

30 July 2017

307-320

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060020-00005

30 July 2017

0 references

cites work

Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

1 reference

12 December 2020

A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium

1 reference

12 December 2020

The use of bronchodilators in stable chronic obstructive pulmonary disease.

1 reference

12 December 2020

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

1 reference

12 December 2020

The QTc interval, autonomic neuropathy and mortality in hypoxaemic COPD

1 reference

12 December 2020

A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease

1 reference

12 December 2020

Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol

1 reference

12 December 2020

Cardiovascular effects of fenoterol under conditions of hypoxaemia

1 reference

12 December 2020

Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease

1 reference

12 December 2020

What role for theophylline?

1 reference

12 December 2020

Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease.

1 reference

12 December 2020

A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease

1 reference

12 December 2020

Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial

1 reference

12 December 2020

An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

1 reference

12 December 2020

Management of chronic obstructive pulmonary disease

1 reference

12 December 2020

Long-acting beta(2)-agonists: how are they used in an optimal way?

1 reference

12 December 2020

Short-term cardiovascular effects of salmeterol

1 reference

12 December 2020

Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study

1 reference

12 December 2020

Cardiac effects of beta-agonists in patients with COPD

1 reference

12 December 2020

The effect of maintenance theophylline therapy on lung work in severe chronic obstructive pulmonary disease while standing and walking

1 reference

12 December 2020

[Increasing physical endurance with salmeterol]

1 reference

12 December 2020

Multicenter 1-year trial on formoterol, a new long-acting beta 2-agonist, in chronic obstructive airway disease.

1 reference

12 December 2020

Cardiovascular and metabolic effects of eformoterol in adults

1 reference

12 December 2020

Cardiac arrhythmias in patients with mild-to-moderate obstructive lung disease. Comparison of beta-agonist therapy alone and in combination with a xanthine derivative, enprofylline or theophylline

1 reference

12 December 2020

Effectiveness of salmeterol in stable COPD

1 reference

12 December 2020

Effect of blood gas derangement on QTc dispersion in severe chronic obstructive pulmonary disease: evidence of an electropathy?

1 reference

12 December 2020

Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease.

1 reference

12 December 2020

Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD

1 reference

12 December 2020

Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease

1 reference

12 December 2020

Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD?

1 reference

12 December 2020

Salmeterol reduces dyspnea and improves lung function in patients with COPD

1 reference

12 December 2020

Modelling theophylline response in individual patients with chronic bronchitis

1 reference

12 December 2020

Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia

1 reference

12 December 2020

Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group.

1 reference

12 December 2020

Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease

1 reference

12 December 2020

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society

1 reference

12 December 2020

Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease

1 reference

12 December 2020

Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD

1 reference

12 December 2020

Quality of life changes in COPD patients treated with salmeterol

1 reference

12 December 2020

[Effect duration and treatment effectiveness of salmeterol, fenoterol and salbutamol in severe forms of respiratory tract obstruction]

1 reference

12 December 2020

Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease

1 reference

12 December 2020

A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD

1 reference

12 December 2020

The beta-agonist controversy

1 reference

12 December 2020

Incremental Benefit of Adding Oxitropium Bromide to Formoterol in Patients with Stable COPD

1 reference

12 December 2020

In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group

1 reference

12 December 2020

Oxitropium bromide (Ba 253), an advance in the field of anticholinergic bronchodilating treatments. Preliminary results

1 reference

12 December 2020

Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease

1 reference

12 December 2020

Inhaled beta2-agonists and airway responses to allergen

1 reference

12 December 2020

Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-center study

1 reference

12 December 2020

Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study

1 reference

12 December 2020

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

12 December 2020

Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

12 December 2020

Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action

1 reference

12 December 2020

Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease

1 reference

12 December 2020

Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey

1 reference

12 December 2020

Eformoterol versus salbutamol in patients with ROAD

1 reference

12 December 2020

BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS

1 reference

12 December 2020

10.2165/00003495-200060020-00005

Identifiers

DOI

1 reference

PubMed ID

10983735

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

10983735